Disease · MONDO_0005314

relapsing-remitting multiple sclerosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. relapsing-remitting multiple sclerosis. Diseases, record MONDO_0005314. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005314

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: relapsing-remitting multiple sclerosis; Open Targets
Open Targets ID: MONDO_0005314; Open Targets
Other names: Acute Relapsing Multiple Sclerosis, MS RELAPSING REMITTING, Multiple Sclerosis, Acute Relapsing, Multiple Sclerosis, Relapsing Remitting, Multiple Sclerosis, Remitting-Relapsing, Remitting Relapsing Multiple Sclerosis; Open Targets
Disease Ontology: DOID:2378; Disease Ontology
MeSH: D020529; MeSH
NCI Thesaurus: C165675; NCI Thesaurus
Highest stage of its drugs: Approval, for 14 of its 23 drugs, from EMA Human Drugs and FDA; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OCRELIZUMAB	CHEMBL2108041	Antibody	Approval	FDA	5	4	4	Drugs and targets
NATALIZUMAB	CHEMBL1201607	Antibody	Approval	EMA Human Drugs	4	3	3	Drugs and targets
DIMETHYL FUMARATE	CHEMBL2107333	Small molecule	Approval	EMA Human Drugs, at withdrawal	8	2	2	Drugs and targets
FINGOLIMOD	CHEMBL314854	Small molecule	Approval	EMA Human Drugs	4	1	1	Drugs and targets
TERIFLUNOMIDE	CHEMBL973	Small molecule	Approval	EMA Human Drugs	3	1	1	Drugs and targets
OFATUMUMAB	CHEMBL1201836	Antibody	Approval	EMA Human Drugs	2	1	1	Drugs and targets
SIPONIMOD	CHEMBL2336071	Small molecule	Approval	EMA Human Drugs and FDA	2	0	0	Drugs and targets
UBLITUXIMAB	CHEMBL2108354	Antibody	Approval	EMA Human Drugs and FDA	2	0	0	Drugs and targets
DACLIZUMAB	CHEMBL1201605	Antibody	Approval	FDA	1	0	0	Drugs and targets
DIROXIMEL FUMARATE	CHEMBL3989944	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
S1PR1	Sphingosine 1-phosphate receptor	5	Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent	Approval	https://conductscience.org/library/genes/1901	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	4	B-lymphocyte antigen CD20 binding agent	Approval	https://conductscience.org/library/genes/931	Drugs and targets
KEAP1	Kelch-like ECH-associated protein 1	3	Kelch-like ECH-associated protein 1 inhibitor	Approval	https://conductscience.org/library/genes/9817	Drugs and targets
S1PR5	Sphingosine 1-phosphate receptor	2	Sphingosine 1-phosphate receptor 5 modulator; Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent	Approval	https://conductscience.org/library/genes/53637	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 3	https://conductscience.org/library/genes/1043	Drugs and targets
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	1	Dihydroorotate dehydrogenase inhibitor	Approval	https://conductscience.org/library/genes/1723	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor modulator	Phase 2/3	https://conductscience.org/library/genes/2099	Drugs and targets
ESR2	Estrogen receptor	1	Estrogen receptor modulator	Phase 2/3	https://conductscience.org/library/genes/2100	Drugs and targets
HLA-DRB1	HLA class II histocompatibility antigen, DRB1-15 beta chain	1	HLA class II histocompatibility antigen, DRB1-15 beta chain modulator	Phase 2	https://conductscience.org/library/genes/3123	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Unknown	https://conductscience.org/library/genes/3454	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00930553	An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab	Phase 3	1,314	2017-05-15	Multiple Sclerosis, Relapsing-Remitting	ALEMTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02861014	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	Phase 3	681	2021-02-03	Multiple Sclerosis, Relapsing-Remitting	OCRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03933202	A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)		291	2026-01-02	Multiple Sclerosis	CLADRIBINE	Its record names the disease	ClinicalTrials.gov
NCT01963611	Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)	Phase 2	255	2016-05-11	Relapsing Remitting Multiple Sclerosis	PLOVAMER ACETATE	Its record names the disease	ClinicalTrials.gov
NCT05084638	Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.	Phase 4	180	2026-02-27	Relapse Remitting Multiple Sclerosis	OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03933215	A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)		100	2025-04-29	Multiple Sclerosis	CLADRIBINE	Its record names the disease	ClinicalTrials.gov
NCT01705236	A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®	Phase 4	87	2020-03-02	Relapsing Remitting Multiple Sclerosis RRMS	FINGOLIMOD	Its record names the disease	ClinicalTrials.gov
NCT04230174	Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation	Phase 4	22	2025-12-30	Multiple Sclerosis	OCRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03774407	Vaginal Estriol in Multiple Sclerosis	Phase 2/3	21	2022-09-21	Multiple Sclerosis, Neurogenic Bladder	ESTRIOL	Its record names the disease	ClinicalTrials.gov
NCT03387046	A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)	Phase 2	7	2020-02-10	Multiple Sclerosis, Relapsing-Remitting	D-ASPARTATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alemtuzumab Treatment CAMMS323 Extension vs Alemtuzumab Treatment CAMMS324 Extension: Number of Participants With Sustained Accumulation of Disability (SAD)	79 of 376	118 of 426	802	NCT00930553	Trial comparisons
Ocrelizumab vs Ocrelizumab Safety Follow-up: deaths from any cause	1 of 680	0 of 64	744	NCT02861014	Trial comparisons
Ocrelizumab vs Ocrelizumab Safety Follow-up: serious adverse events	49 of 680	6 of 64	744	NCT02861014	Trial comparisons
Alemtuzumab Treatment CAMMS323 Extension vs Alemtuzumab Treatment CAMMS324 Extension: Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS at Year 6	74 of 235	130 of 321	556	NCT00930553	Trial comparisons
Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: Number of Participants With At Least One Concomitant Medication	98 of 103	73 of 85	188	NCT03933202	Trial comparisons
Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: deaths from any cause	2 of 103	0 of 85	188	NCT03933202	Trial comparisons
Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: serious adverse events	10 of 103	14 of 85	188	NCT03933202	Trial comparisons
Ofatumumab-Treated vs Healthy Control: deaths from any cause	0 of 119	0 of 61	180	NCT05084638	Trial comparisons
Ofatumumab-Treated vs Healthy Control: serious adverse events	8 of 119	3 of 61	180	NCT05084638	Trial comparisons
IFNB-1a/Alemtuzumab Switch CAMMS323/03409 (Post Alemtuzumab) vs IFNB-1a/Alemtuzumab Switch CAMMS324/03409 (Post Alemtuzumab): Number of Participants With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study	11 of 65	14 of 102	167	NCT00930553	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26696956	RESULT	1	PubMed
25415166	RESULT	1	PubMed
24769473	RESULT	1	PubMed
24453710	RESULT	1	PubMed
23076892	RESULT	1	PubMed
19442988	RESULT	1	PubMed
16567708	RESULT	1	PubMed
11386586	RESULT	1	PubMed
42985590	DERIVED	1	PubMed
42328798	DERIVED	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005314

GET https://conductscience.org/api/diseases/v1/MONDO_0005314/drugs?page=2

API reference For AI assistants